生物医药企业在安全标准化基础上建设双重预防机制的思考  

Consideration on Establishing Double Prevention Mechanism Based on Safety Standardization in Bio-pharmaceutical Enterprises

作　　者：林小瑞[1] 张铭润 周玮 邹俊如 黄成[1] 郑俊杰 LIN Xiaorui;ZHANG Mingrun;ZHOU Wei;ZOU Junru;HUANG Cheng;ZHENG Junjie(Institute of Medical Biology,Chinese Academy of Medical Sciences,Kunming Yunnan 650118)

机构地区：[1]中国医学科学院医学生物学研究所,云南昆明650118

出　　处：《中国科技纵横》2024年第21期153-155,共3页China Science & Technology Overview

摘　　要：本文从生物医药企业的安全管理现状出发,分析现有安全标准化管理中需要提升的关键要点,探讨双重预防机制建设的必要性及其方向,将风险分析、安全检查、安全责任制与安全操作规程进行结合,实现一体化安全管理,逐步提高生物医药企业的安全管理水平,对生物医药企业安全管理有重要的理论和实践意义。Starting from the current situation of safety management in biopharmaceutical enterprises,analyze the key areas that need to be improved in existing safety standardization management,exploring the necessity and direction of building a dual prevention mechanism,integrate risk analysis,safety inspections,safety responsibility systems,and safety operating procedures,achieve integrated safety management,gradually improve the safety management level of biopharmaceutical enterprises.This study has important theoretical and practical significance for the safety management of biomedical enterprises.

关 键 词：生物医药企业 安全标准化 双重预防机制 安全责任制 隐患排查 

分 类 号：TQ460.8[化学工程—制药化工]